Clinical Trials · NCT06375707
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Enrollment
- 74
- Start date
- Jan 2024
- Locations
- 1 site, China
- Primary endpoint
- Overall response rate (ORR)